Pharmacogenetics and Genomics

Papers
(The H4-Index of Pharmacogenetics and Genomics is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
GLP1R and OCT1 variants modulate semaglutide and metformin response in type 2 diabetes20
Association of Genetic Variation in CES, UGT, ABC, and SLCO with Irinotecan Infusion Reactions and Severe Toxicity: Erratum19
MEG3 in hematologic malignancies: from the role of disease biomarker to therapeutic target14
Pharmacogenetic testing coverage by Canadian insurance providers13
Application of risk priority number of failure mode and effects analysis to drug–variant pairs for severe cutaneous adverse reactions in Korean and American populations13
Establishing national reference materials for genetic testing of cytochrome P45011
Luteal phase stimulation in double ovarian stimulation cycles is not affected by the follicle-stimulating hormone (FSH) receptor genotype: double ovarian stimulation is beneficial independently of the11
Novel variant in Nudix hydrolase 15 gene influences 6-mercaptopurine toxicity in childhood acute lymphoblastic leukemia patients11
Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation10
The prevalence of pharmacogenetic testing in the United States10
0.1014289855957